Elicio Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
451 D St Ste 501 Fl 5, Boston, Massachus...Phone Number
(857) 209-0050Website
www.elicio.comRevenue
$38.2 MillionStock Symbol
ELTXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
2
1
About Elicio Therapeutics
Founded in 2011, Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases.Explore more
Elicio Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Elicio Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Elicio Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Elicio Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Elicio Therapeutics has new funding data
Click to see if Elicio Therapeutics had a recent Job posting/layoffs
Check out if Elicio Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Elicio Therapeutics
Check if Elicio Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Elicio Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Elicio Therapeutics
Compare insights from companies similar to Elicio Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$123.9M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Company Profile Activity
Activity Insights
Elicio Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Elicio Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Elicio Therapeutics.
Elicio Therapeutics financials insights
Gather financial insights about Elicio Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$30M
2021
Series B
$73M
2024
Share Placement
$6M
2025
Other Financing Round
$10M
Elicio Therapeutics Tech Stack
A closer look at the technologies used by Elicio Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Elicio Therapeutics is building a staged, data-driven metastatic clinical development plan initially focused on recurrent metastatic pancreatic cancer patients with no more than three lesions, with plans to expand subject to funding into treatment-naive patients, broader combination regimens, and bulkier tumors, using small cohorts designed for rapid generation of clinical, biomarker, and immune data to guide subsequent development steps.
Funding, Medical Research, Clinical Operations, Finance
Project
Elicio Therapeutics has reported that antigen spreading was observed beginning during ELI-002 monotherapy in two of the three individuals and further increasing upon addition of checkpoint inhibitor-based therapy with 82% of personalized tumor antigens evaluated found to be immunogenic, suggesting that anti-tumor immunity not only persists following ELI-002 treatment but may broaden when checkpoint inhibition is added.
Medical Research
Project
Elicio Therapeutics has reported that mutant KRAS-specific T-cell responses encompassing both CD4-positive and CD8-positive populations persisted, with these T cells demonstrating polyfunctionality, including the capacity to produce key immune mediators and cytotoxic molecules.
Medical Research, Pharmaceuticals
Project
Medical Research, Pharmaceuticals
Elicio Therapeutics News & Media
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that management will participate in one-on-one meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston, MA.Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic pancreatic cancer; Phase 1 study anticipated to initiate Q4 2026Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the closing of its previously announced registered direct offering (the “Offering”) pursuant to a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of anElicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a regist
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Elicio Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2011, Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases.... Read More
